Cas13 Nasal Pan‑Influenza Therapy

Engineering Cas13 (delivered as mRNA in lipid nanoparticles) plus conserved influenza guide RNAs could act as a pan‑strain antiviral given intranasally or by injection, stopping replication in respiratory epithelial cells; early 'lung‑on‑a‑chip' tests reported activity against H1N1 and H3N2 with no observed off‑target effects in that model. If scalable and safe in vivo, the approach would sidestep strain‑matching vaccines and enable rapid therapeutic responses to novel influenza variants. — This raises immediate public‑health and biosecurity questions: regulatory pathways for nucleic‑acid antivirals, distribution and equity of stockpiled therapeutics, clinical trial standards for gene‑editing drugs, and safeguards against misuse or accidental release.